Latest News

Zydus Cadila receives USFDA approval for seizure, migraine drug

Zydus Cadila has received final approval to market topiramate extended release capsules, from the US health regulator. It is used for treating seizures and migraine.

In a BSE filing Zydus Cadila stated that, it has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 25 mg, 50 mg and 100 mg.

Further it added that, the drug will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad.

Read EquityPandit’s Technical Analysis on Nifty Pharma

Click here to check market prediction for next trading session.

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.



📰
News
📈
Prediction
📊
FII / DII
👔
Advisory
Get 1-2 Index Option Trades Daily